PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report
The study highlights that genetic testing should be considered for FH patients who experience failure with PCSK9 inhibitors, as novel LDLR variants may account for resistance and inform personalized treatment.
Authors
- Huiyan Jiang (ORCID: https://orcid.org/0000-0002-1428-8776)
- Xin Chen (ORCID: https://orcid.org/0000-0002-5406-4136)
- Simin Yan (ORCID: https://orcid.org/0000-0002-2192-0717)
- Yuan Li (ORCID: https://orcid.org/0000-0003-4547-7518)
- Yajuan Xiong
Institutions
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-09-22
- DOI
- https://doi.org/10.3389/fcvm.2025.1644145
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hohai University